Boston Scientific data positions Farapulse for approval, says Citi

Citi says Boston Scientific’s ADVENT trial evaluating its Farapulse Pulsed Field Ablation system versus conventional thermal ablation met its primary endpoint, positioning it for FDA approval in 2024. The trial met its primary efficacy endpoint demonstrating non-inferiority with a rate of 73.3% in the PFA arm versus 71.3% in the thermal arm, the analyst tells investors in a research note. “This is good data,” which should “hurdle investor expectations,” the analyst tells investors in a research note. The firm keeps a Buy rating on Boston Scientific shares with a $63 price target.